New ruthenium complexes target cancer cells without typical side effects

May 28, 2013, University of Texas at Arlington
A graphic from the Molecular Cancer Therapeutics paper shows the growth of a control tumor compared to the growth of tumors treated with ruthenium-based complexes developed in the lab. Credit: UT Arlington

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

Fred MacDonnell, professor of chemistry and biochemistry at The University of Texas at Arlington, has been researching a new generation of metal-based antitumor agents along with a team from the City of Hope Comprehensive Center Center in Duarte, Calif. Their aim is to find new therapies to complement widely used platinum-based therapies, such as cisplatin. Cisplatin is one of the most widely used anti-cancer drugs and shows remarkable effectiveness against some cancers, however it does not work on all cancers and can have severe side effects.

In a study published in the May edition of Molecular Cancer Therapeutics, the team describes two newly developed ruthenium polypyridyl complexes, or RPCs, that yielded results comparable to cisplatin against human non-small cell in pre-clinical lab tests.

Unlike cisplatin, the RPCs were generally cleared from the body unchanged, without noticeable effects on metabolism or . In lab tests, healthy cells could withstand almost 10 times as much exposure to the team's ruthenium complexes as the cancer cells.

The study also found that the RPCs seemed to target cells in hypoxic states. Hypoxia, or low oxygen, is a signature of tumor cells.

" on the market now generally are less effective under hypoxic conditions or insensitive to the ," MacDonnell said. "Since many are under hypoxic stress and most normal cells are not, having something that becomes even more effective under hypoxia could have some real benefit to the patient."

The effectiveness of the RPCs tested seems to be associated with a particular portion of their structure. This portion, known as "tatpp" is redox-active, which means it is reduced when bound to DNA in the normal cellular environment. MacDonnell's team believe that this reduction step in the DNA bound compound sets in motion a biological process that triggers apoptosis, also known as programmed cell death, in cancer cells. Under , this reduction is more prevalent, leading to greater cell death in those cells.

"Being activated under low-oxygen conditions makes these unique complexes excellent candidates for use on some of the most difficult to treat tumors," said Dr. Sanjay Awasthi, professor of medical oncology and therapeutics research at City of Hope. "Now that we have demonstrated the role of the tatpp ligand in these biological processes, our team can continue toward the goal of using ruthenium-based complexes to enhance current treatments."

MacDonnell said the ruthenium complexes' increased effectiveness against malignant cells could be because the complexes can more easily enter cancer cells, which tend to be more metabolically active than normal cells. That hypothesis, however, is something the team will explore with further research.

Explore further: New ruthenium-based drugs show promise for killing cancer cells

More information: The paper, called "Regression of lung cancer by hypoxia-sensitizing ruthenium polypridyl complexes," is available online at: mct.aacrjournals.org/content/12/5/643.short

Related Stories

New ruthenium-based drugs show promise for killing cancer cells

June 11, 2012
A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

Resistance is futile: Researchers identify gene that mediates cisplatin resistance in ovarian cancer

April 15, 2013
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...

Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors

April 3, 2013
Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published ...

Study reveals how melanoma evades chemotherapy

April 8, 2013
Nitric oxide (NO), a gas with many biological functions in healthy cells, can also help some cancer cells survive chemotherapy. A new study from MIT reveals one way in which this resistance may arise, and raises the possibility ...

Lack of oxygen in cancer cells leads to growth and metastasis

September 13, 2012
(Medical Xpress)—It seems as if a tumor deprived of oxygen would shrink. However, numerous studies have shown that tumor hypoxia, in which portions of the tumor have significantly low oxygen concentrations, is in fact linked ...

Scientists define a new mechanism leading to tumor hypoxia

May 9, 2013
An article published recently in Tumor Microenvironment and Therapy - an open access journal by Versita, defines a novel mechanism of tumor hypoxia induced by the longitudinal gradient of residual oxygen along tumor vessels ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.